Bictegravir
Trends in HIV Postexposure Prophylaxis (PEP) Use in the United States from 2015-2023
Researchers at the Centers for Disease Control and Prevention (CDC) have published a study on HIV postexposure prophylaxis (PEP) use in the United States, highlighting a significant increase in PEP prescriptions from 2015 to 2023. The study analyzed national trends in PEP regimens recommended by the CDC, as well as